Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | 3HP-2827 |
Synonyms | |
Therapy Description |
3HP-2827 selectively inhibits FGFR2, potentially resulting in decreased cell proliferation and tumor growth (Cancer Res (2024) 84 (6_Supplement): 1965). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
3HP-2827 | 3HP 2827|3HP2827 | FGFR2 Inhibitor 23 | 3HP-2827 selectively inhibits FGFR2, potentially resulting in decreased cell proliferation and tumor growth (Cancer Res (2024) 84 (6_Supplement): 1965). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 fusion | stomach cancer | predicted - sensitive | 3HP-2827 | Preclinical - Pdx | Actionable | In a preclinical study, 3HP-2827 treatment demonstrated antitumor activity in a patient-derived xenograft (PDX) model of gastric cancer harboring an FGFR2 fusion (Cancer Res (2024) 84 (6_Supplement): 1965). | detail... |
FGFR2 N549K | endometrial cancer | predicted - sensitive | 3HP-2827 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, 3HP-2827 treatment demonstrated antitumor activity in a cell line xenograft model of endometrial cancer harboring FGFR2 N549K (Cancer Res (2024) 84 (6_Supplement): 1965). | detail... |
FGFR2 amp | stomach cancer | predicted - sensitive | 3HP-2827 | Preclinical - Pdx | Actionable | In a preclinical study, 3HP-2827 treatment demonstrated antitumor activity in a patient-derived xenograft (PDX) model of gastric cancer with FGFR2 amplification (Cancer Res (2024) 84 (6_Supplement): 1965). | detail... |
FGFR2 fusion | intrahepatic cholangiocarcinoma | predicted - sensitive | 3HP-2827 | Preclinical - Pdx | Actionable | In a preclinical study, 3HP-2827 treatment demonstrated antitumor activity and induced tumor regression in a patient-derived xenograft (PDX) model of intrahepatic cholangiocarcinoma harboring an FGFR2 fusion (Cancer Res (2024) 84 (6_Supplement): 1965). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06287918 | Phase I | 3HP-2827 | A First-in-human Study of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations | Not yet recruiting | USA | 0 |